Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study
Supratherapeutic doses of ICS were used by almost one-fourth of the patients prior to initiation of biologic therapy and were associated with a higher prevalence of cataracts. Physician-driven ICS reduction was rare, yet supratherapeutic ICS users were found to self-regulate ICS therapy when treated with biologic therapy.
Authors
- Barbara Bonnesen
- Anna von Bülow (ORCID: https://orcid.org/0009-0005-3268-785X)
- Marianne Baastrup Soendergaard (ORCID: https://orcid.org/0000-0002-4954-0863)
- Ole Hilberg (ORCID: https://orcid.org/0000-0002-3075-3463)
- Susanne Hansen (ORCID: https://orcid.org/0000-0002-9550-6703)
- Sofie Lock Johansson (ORCID: https://orcid.org/0000-0003-0597-9468)
- Kjell Erik Julius Håkansson (ORCID: https://orcid.org/0000-0001-5804-0740)
- Anne B. Walls (ORCID: https://orcid.org/0000-0002-5234-5006)
- Johannes Martin Schmid (ORCID: https://orcid.org/0000-0002-4558-2943)
- Celeste Porsbjerg (ORCID: https://orcid.org/0000-0003-4825-9436)
- Claus Rikard Johnsen (ORCID: https://orcid.org/0009-0008-4149-4592)
- Charlotte Suppli Ulrik
- Anne‐Sofie Bjerrum (ORCID: https://orcid.org/0009-0002-1657-2399)
- Frederikke Hjortdahl
- Linda Makowska Rasmussen
Institutions
- University of Copenhagen (DK)
- Frederiksberg Hospital (DK)
- Odense University Hospital (DK)
- Bispebjerg Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Vejle Sygehus (DK)
- Lillebaelt Hospital (DK)
Publication Details
- Journal
- Lung
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1007/s00408-025-00796-5
- Citations
- 4
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 4.66
Funders
- AstraZeneca
- Sanofi
- Teva Pharmaceutical Industries
- Københavns Universitet